ADAR1 Capital Management
ADAR1 Capital Management reported 262 stocks worth $2.3B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ABVX (8.8%), SPY (5.9%) and PTGX (5.8%). Compared with Q2 2026, the fund opened new positions in FRNM, ABCL and VOGX, added to ABVX, SPY and ZLAB, trimmed PTGX, ROIV and IMVT and sold out of FTH, FRNM and BHF.
Latest filing: what ADAR1 Capital Management did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() ABVX Abivax SA | $203M | 8.8% | 2.1M | +246K (+14%) | 8 of 8 | |
| 2 | ![]() SPY Spdr S&P 500 ETF TR | $135M | 5.9% | 178K | +49K (+38%) | 6 of 8 | |
| 3 | ![]() PTGX Protagonist Therapeutics Inc | $134M | 5.8% | 951K | −9,460 (−1%) | 8 of 8 | |
| 4 | ![]() ROIV Roivant Sciences Ltd | $113M | 4.9% | 3.1M | −77K (−2%) | 8 of 8 | |
| 5 | ![]() ZLAB Zai Lab Ltd | $89.1M | 3.9% | 3.4M | +12K (+0%) | 8 of 8 | |
| 6 | ![]() IMVT Immunovant Inc | $71.5M | 3.1% | 2.1M | −215K (−9%) | 8 of 8 | |
| 7 | ![]() XENE Xenon Pharmaceuticals Inc | $43.2M | 1.9% | 1.2M | +995K (+598%) | 8 of 8 | |
| 8 | ![]() DNLI Denali Therapeutics Inc | $42.8M | 1.9% | 2.1M | +1M (+101%) | 8 of 8 | |
| 9 | ![]() BOXX EA Series Trust | $39.9M | 1.7% | 337K | No change | 8 of 8 | |
| 10 | ![]() SEPN Septerna Inc | $38.1M | 1.6% | 974K | +34K (+4%) | 7 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
CRINETICS PHARMACEUTICALS IN | $45.7M | 1.2M |
TEVA PHARMACEUTICAL INDS LTD | $9.4M | 278K |
![]() FTH Sensei Biotherapeutics Inc | $9M | 361K |
![]() FRNM Perceptive Cap Solutions Cor | $7.3M | 675K |
GALECTO INC | $7.3M | 280K |
🔒 Free account: see all 30.
Options
valued at the underlying sharesReported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR/A Amendment | Q3 2026 | SEC filing ↗ |
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Includes an amendment, which can add positions the fund kept confidential at first, or replace the original report.
Other superinvestors
All hedge fund holdings →ADAR1 Capital Management 13F FAQ
What does ADAR1 Capital Management own?
ADAR1 Capital Management reported 262 stocks worth $2.3B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ABVX (8.8%), SPY (5.9%) and PTGX (5.8%). The table above lists every position in the filing (the top 10 without an account).
What did ADAR1 Capital Management buy and sell in Q3 2026?
Compared with Q2 2026: 41 new positions, 84 added to, 60 trimmed and 41 sold out. New positions include FRNM, ABCL and VOGX. It sold all of FTH, FRNM and BHF.
When will ADAR1 Capital Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is ADAR1 Capital Management's portfolio worth?
The Q3 2026 filing reports $2.3B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.























